Adenovirus Viral Kinetics and Mortality in Ex Vivo T Cell-Depleted Hematopoietic Cell Transplant Recipients With Adenovirus Infection From a Single Center

J Infect Dis. 2020 Sep 1;222(7):1180-1187. doi: 10.1093/infdis/jiaa237.

Abstract

Background: We report on predictors of adenovirus (ADV) viremia and correlation of ADV viral kinetics with mortality in ex vivo T-cell depleted (TCD) hematopoietic cell transplant (HCT).

Methods: T cell-depleted HCT recipients from January 1, 2012 through September 30, 2018 were prospectively monitored for ADV in the plasma through Day (D) +100 posttransplant or for 16 weeks after the onset of ADV viremia. Adenovirus viremia was defined as ≥2 consecutive viral loads (VLs) ≥1000 copies/mL through D +100. Time-averaged area under the curve (AAUC) or peak ADV VL through 16 weeks after onset of ADV viremia were explored as predictors of mortality in Cox models.

Results: Of 586 patients (adult 81.7%), 51 (8.7%) developed ADV viremia by D +100. Age <18 years, recipient cytomegalovirus seropositivity, absolute lymphocyte count <300 cells/µL at D +30, and acute graft-versus-host disease were predictors of ADV viremia in multivariate models. Fifteen (29%) patients with ADV viremia died by D +180; 8 of 15 (53%) died from ADV. Peak ADV VL (hazard ratio [HR], 2.25; 95% confidence interval [CI], 1.52-3.33) and increasing AAUC (HR, 2.95; 95% CI, 1.83-4.75) correlated with mortality at D +180.

Conclusions: In TCD HCT, peak ADV VL and ADV AAUC correlated with mortality at D +180. Our data support the potential utility of ADV viral kinetics as endpoints in clinical trials of ADV therapies.

Keywords: adenovirus infection; hematopoietic cell transplant; viral kinetics.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenoviridae / growth & development
  • Adenoviridae Infections / immunology
  • Adenoviridae Infections / mortality*
  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Female
  • Graft vs Host Disease / immunology
  • Graft vs Host Disease / mortality
  • Graft vs Host Disease / virology
  • Hematologic Diseases / immunology
  • Hematologic Diseases / mortality
  • Hematologic Diseases / virology
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Kinetics
  • Lymphocyte Depletion*
  • Male
  • Middle Aged
  • Myeloablative Agonists / therapeutic use
  • Survival Analysis
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / transplantation
  • Transplantation Conditioning*
  • Transplantation, Homologous
  • Viral Load
  • Viremia / immunology
  • Viremia / mortality*

Substances

  • Myeloablative Agonists